IMC Chicago
SRPT icon

IMC Chicago’s Sarepta Therapeutics SRPT Stock Holding History

IMC Chicago’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.63M Sell
257,900
-23,400
-8% -$443K ﹤0.01% 2163
2026
Q1 		$6.12M Sell
281,300
-2,400
-0.8% -$46.5K ﹤0.01% 1626
2025
Q4 		$6.11M Buy
283,700
+208,700
+278% +$4.4M ﹤0.01% 1589
2025
Q3 		$1.45M Buy
75,000
+43,300
+137% +$772K ﹤0.01% 2464
2025
Q2 		$542K Buy
31,700
+3,500
+12% +$149K ﹤0.01% 2814
2025
Q1 		$1.8M Buy
+28,200
New +$2.97M ﹤0.01% 1864
2024
Q3 		– Sell
-12,000
Closed -$1.9M – 3030
2024
Q2 		$1.9M Buy
+12,000
New +$1.54M ﹤0.01% 1577
2024
Q1 		– Sell
-20,100
Closed -$1.94M – 2495
2023
Q4 		$1.94M Sell
20,100
-100
-0.5% -$9.59K ﹤0.01% 1225
2023
Q3 		$2.45M Sell
20,200
-1,700
-8% -$192K ﹤0.01% 924
2023
Q2 		$2.51M Sell
21,900
-52,800
-71% -$6.81M ﹤0.01% 823
2023
Q1 		$10.3M Buy
74,700
+46,400
+164% +$6.02M 0.01% 483
2022
Q4 		$3.67M Buy
28,300
+15,200
+116% +$1.76M 0.01% 686
2022
Q3 		$1.45M Buy
+13,100
New +$1.32M ﹤0.01% 825
2022
Q1 		– Sell
-29,900
Closed -$2.69M – 1246
2021
Q4 		$2.69M Sell
29,900
-200
-0.7% -$17.1K ﹤0.01% 749
2021
Q3 		$2.78M Sell
30,100
-3,900
-11% -$300K ﹤0.01% 775
2021
Q2 		$2.64M Sell
34,000
-23,600
-41% -$1.79M ﹤0.01% 712
2021
Q1 		$4.29M Buy
57,600
+23,800
+70% +$2.2M 0.01% 600
2020
Q4 		$5.76M Buy
33,800
+18,800
+125% +$2.79M 0.01% 516
2020
Q3 		$2.11M Buy
15,000
+3,400
+29% +$517K ﹤0.01% 575
2020
Q2 		$1.86M Sell
11,600
-4,400
-28% -$599K ﹤0.01% 577
2020
Q1 		$1.56M Sell
16,000
-26,500
-62% -$3.03M ﹤0.01% 555
2019
Q4 		$5.48M Buy
42,500
+20,400
+92% +$2.06M 0.01% 325
2019
Q3 		$1.67M Sell
22,100
-15,500
-41% -$1.83M 0.01% 490
2019
Q2 		$5.71M Sell
37,600
-15,200
-29% -$1.85M 0.02% 256
2019
Q1 		$6.29M Buy
+52,800
New +$6.79M 0.02% 208

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

IMC Chicago's SRPT Position: Q2 2026 in Review

IMC Chicago reduced its Sarepta Therapeutics (SRPT) stake by 17% in Q2 2026, selling an estimated $44.4K and leaving 11,546 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #5641.

IMC Chicago first reported a position in SRPT in Q1 2019 and has held it in 10 quarters since. The position peaked at $1.41M in Q1 2019. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • IMC Chicago held 11,546 shares of Sarepta Therapeutics worth $207K as of Q2 2026.
  • IMC Chicago sold 2,349 Sarepta Therapeutics shares in Q2 2026, an estimated $44.4K.
  • Sarepta Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #5641 holding.
  • IMC Chicago first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 10 quarters since.
  • IMC Chicago's Sarepta Therapeutics position peaked at $1.41M in Q1 2019.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.